Clinical Trial Update: Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nintedanib in recurrent malignant pleural mesothelioma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-09